BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 9792847)

  • 1. L1-specific protection from tumor challenge elicited by HPV16 virus-like particles.
    De Bruijn ML; Greenstone HL; Vermeulen H; Melief CJ; Lowy DR; Schiller JT; Kast WM
    Virology; 1998 Oct; 250(2):371-6. PubMed ID: 9792847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of human papillomavirus type 16 L1 chimeric virus-like particles versus L1/L2 chimeric virus-like particles in tumor prevention.
    Wakabayashi MT; Da Silva DM; Potkul RK; Kast WM
    Intervirology; 2002; 45(4-6):300-7. PubMed ID: 12566713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice.
    Ohlschläger P; Osen W; Dell K; Faath S; Garcea RL; Jochmus I; Müller M; Pawlita M; Schäfer K; Sehr P; Staib C; Sutter G; Gissmann L
    J Virol; 2003 Apr; 77(8):4635-45. PubMed ID: 12663770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model.
    Greenstone HL; Nieland JD; de Visser KE; De Bruijn ML; Kirnbauer R; Roden RB; Lowy DR; Kast WM; Schiller JT
    Proc Natl Acad Sci U S A; 1998 Feb; 95(4):1800-5. PubMed ID: 9465097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of HPV16 capsid protein-specific human T cell responses by virus-like particles.
    Rudolf MP; Nieland JD; DaSilva DM; Velders MP; Müller M; Greenstone HL; Schiller JT; Kast WM
    Biol Chem; 1999 Mar; 380(3):335-40. PubMed ID: 10223336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced mucosal and systemic immune responses following intravaginal immunization with human papillomavirus 16 L1 virus-like particle vaccine in thermosensitive mucoadhesive delivery systems.
    Park JS; Oh YK; Kang MJ; Kim CK
    J Med Virol; 2003 Aug; 70(4):633-41. PubMed ID: 12794729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice.
    Revaz V; Benyacoub J; Kast WM; Schiller JT; De Grandi P; Nardelli-Haefliger D
    Virology; 2001 Jan; 279(1):354-60. PubMed ID: 11145916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HPV-16 L1 genes with inactivated negative RNA elements induce potent immune responses.
    Rollman E; Arnheim L; Collier B; Oberg D; Hall H; Klingström J; Dillner J; Pastrana DV; Buck CB; Hinkula J; Wahren B; Schwartz S
    Virology; 2004 Apr; 322(1):182-9. PubMed ID: 15063127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The L1 major capsid protein of human papillomavirus type 16 variants affects yield of virus-like particles produced in an insect cell expression system.
    Touze A; El Mehdaoui S; Sizaret PY; Mougin C; Muñoz N; Coursaget P
    J Clin Microbiol; 1998 Jul; 36(7):2046-51. PubMed ID: 9650960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasmid encoding papillomavirus Type 16 (HPV16) DNA constructed with codon optimization improved the immunogenicity against HPV infection.
    Cheung YK; Cheng SC; Sin FW; Xie Y
    Vaccine; 2004 Dec; 23(5):629-38. PubMed ID: 15542183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of CD4-independent E7-specific CD8+ memory response by heat shock fusion protein.
    Liu H; Wu BH; Rowse GJ; Emtage PC
    Clin Vaccine Immunol; 2007 Aug; 14(8):1013-23. PubMed ID: 17596433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells.
    De Bruijn ML; Schuurhuis DH; Vierboom MP; Vermeulen H; de Cock KA; Ooms ME; Ressing ME; Toebes M; Franken KL; Drijfhout JW; Ottenhoff TH; Offringa R; Melief CJ
    Cancer Res; 1998 Feb; 58(4):724-31. PubMed ID: 9485027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7.
    Daemen T; Pries F; Bungener L; Kraak M; Regts J; Wilschut J
    Gene Ther; 2000 Nov; 7(21):1859-66. PubMed ID: 11110419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine regimen for prevention of sexually transmitted infections with human papillomavirus type 16.
    Kowalczyk DW; Wlazlo AP; Shane S; Ertl HC
    Vaccine; 2001 May; 19(25-26):3583-90. PubMed ID: 11348726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modified HPV16 E7 Genes as DNA Vaccine against E7-Containing Oncogenic Cells.
    Smahel M; Síma P; Ludvíková V; Vonka V
    Virology; 2001 Mar; 281(2):231-8. PubMed ID: 11277695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expression of the human papillomavirus type 16L/E7 fusion protein in E. coli and observation of its immunogenicity in mice].
    Tian HW; Ye ZM; Lu ZH; Jao R; Bian T; Zhao L; Ruan L
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2006 Jun; 20(2):33-7. PubMed ID: 16816859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B lymphocyte activation by human papillomavirus-like particles directly induces Ig class switch recombination via TLR4-MyD88.
    Yang R; Murillo FM; Delannoy MJ; Blosser RL; Yutzy WH; Uematsu S; Takeda K; Akira S; Viscidi RP; Roden RB
    J Immunol; 2005 Jun; 174(12):7912-9. PubMed ID: 15944297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The production and immunogenicity of human papillomavirus type 58 virus-like particles produced in Saccharomyces cerevisiae.
    Kwag HL; Kim HJ; Chang DY; Kim HJ
    J Microbiol; 2012 Oct; 50(5):813-20. PubMed ID: 23124750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Production of human papillomavirus type 33 L1 major capsid protein and virus-like particles from Bacillus subtilis to develop a prophylactic vaccine against cervical cancer.
    Baek JO; Seo JW; Kwon O; Park SM; Kim CH; Kim IH
    Enzyme Microb Technol; 2012 Mar; 50(3):173-80. PubMed ID: 22305172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway.
    Peng S; Frazer IH; Fernando GJ; Zhou J
    Virology; 1998 Jan; 240(1):147-57. PubMed ID: 9448699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.